Clinical Trial

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-29.
Status change: Recruiting → Active, Not Recruiting 2025-04-15
Trial Details
NCT Number NCT06532331
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Metastatic Pancreatic Cancer
Enrollment 87 participants
Start Date 2023-12-06
Primary Completion 2027-09-30 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-18